Background: The chemokine receptor 4 (CXCR4) is an important molecular target for both visualization and therapy of tumors. The aim of the present study was the synthesis and preclinical evaluation of a 64 Cu-labeled, CXCR4-targeting peptide for positron emission tomography (PET) imaging of CXCR4 expression in vivo. Methods: For this purpose, 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), or 1,4,7-triazacyclononane-triacetic acid (NOTA) was conjugated to the highly affine CXCR4-targeting pentixather scaffold. Affinities were determined using Jurkat T-lymphocytes in competitive binding assays employing [
Background
Physiologically, the chemokine receptor 4 (CXCR4) and its only endogenous ligand CXCL12 act through G-protein signaling which leads to chemotaxis, cell adhesion, survival, and proliferation (Kuil et al. 2012a; Hattermann & Mentlein 2013; Burger & Kipps 2006) . In cancer, the CXCR4-CXCL12 axis is involved in tumor growth and progression, invasion and organ-specific metastasis, therapy resistance as well as recurrence (Chatterjee et al. 2014; Burger & Peled 2009; Domanska et al. 2013) . Therefore, CXCR4 is an attractive molecular target, both for therapeutic interventions and for noninvasive quantification of CXCR4 expression, the latter providing important information on the stage and kinetics of the disease. In recent years, a variety of highaffinity CXCR4-targeted imaging probes have been developed for this application, with a focus on targeted peptides, including derivatives of T140 labeled with various radionuclides (George et al. 2014; Yan et al. 2015; Jacobson et al. 2010; Tamamura et al. 2003; Tamamura et al. 1998; Jacobson et al. 2012; Hanaoka et al. 2006) , FC131 (Gourni et al. 2011; Demmer et al. 2011a; Demmer et al. 2011b; Tanaka et al. 2010; Poschenrieder et al. 2016a) , and small molecules such as AMD3100 (plerixafor)-based derivatives, that have been labeled with 64 Cu De Silva et al. 2011; Nimmagadda et al. 2010; Jacobson et al. 2009; Woodard et al. 2014) , 18 F (Oltmanns et al. 2011 ), 11 C (Hartimath et al. 2014) , and 68 Ga (Poty et al. 2016 ). Summaries of CXCR4-targeting probes have recently been reported in excellent reviews (Kuil et al. 2012b; Debnath et al. 2013; Weiss & Jacobson 2013) . Amongst CXCR4-targeted imaging agents, [ 68 Ga]pentixafor (Gourni et al. 2011; Demmer et al. 2011a ) holds a prominent position, because its excellent CXCR4-targeting properties and fast renal excretion allow for high contrast PET imaging of CXCR4 expression in humans. Combined with a favorable dosimetry these properties have paved the way for first currently ongoing clinical studies Wester et al. 2015; Lapa et al. 2016a; Lapa et al. 2016b; Vag et al. 2016; Herhaus et al. 2016) . Recently, a corresponding therapeutic analog with a slightly modified peptide backbone, [ 177 Lu]pentixather, has been introduced, and in first-in-man studies in patients with multiple myeloma, CXCR4-targeted endoradiotherapy using [ 177 Lu]pentixather produced promising metabolic responses Herrmann et al. 2016 to a first CXCR4-directed theranostic concept. However, due to the sensitivity of the pentixafor scaffold towards even small structural modifications such as radiometal exchange in the DOTA chelator (Poschenrieder et al. 2016b) , different dedicated precursors are required for diagnostic and therapeutic applications. In this context, copper radionuclides represent an interesting imaging option. Although 64 Cu (t 1/2 = 12.7 h, β + = 19%, E β + max = 656 keV, β -= 38%, E β -max = 578 keV) decays by both β + and β -emission, its low β + energy, which is comparable to that of 18 F (E β + max = 633 keV), provides high spatial resolution in PET imaging (Williams et al. 2005) and its comparably long half-life is advantageous for performing kinetic PET imaging studies over extended periods of time.
To date, only a few 64 Cu-labeled CXCR4-ligands have been reported. They are either based on the bicyclam AMD3100 De Silva et al. 2011; Nimmagadda et al. 2010; Jacobson et al. 2009 ) or chelator-conjugated T140 analogs Jacobson et al. 2011) . Despite promising in vitro CXCR4 targeting properties, the biodistribution of these compounds is invariably characterized by high non-specific accumulation and retention of 64 Cu activity in the excretion organs (20-40% ID/g), especially in liver and kidneys, hinting -at least partly-towards a limited in vivo stability of the respective 64 Cu-complexes.
Thus, to be able to nevertheless exploit the favorable radionuclide characteristics of 64 Cu, this study was aimed at developing a 64 Cu-labeled CXCR4-targeted probe, which combines high 64 Cu-complex stability with the favorable in vivo pharmacokinetics of pentixafor-based ligands. Thermodynamically stable (Bevilacqua et al. 1987; Wu et al. 2016; Jones-Wilson et al. 1998) and, depending on the conjugated biomolecule, kinetically inert (Zarschler et al. 2014; Dearling et al. 2011) 64 Cu complexes are formed with a variety of chelators (Cai & Anderson 2014; Wadas et al. 2007 
Results

Radiolabeling
Under standard labeling conditions, [ 64 Cu]NOTA-pentixather was obtained in radiochemical yields ≥90%. Radiochemical purities after C8-light purification were >99%, as confirmed by radio-TLC. The specific activity was 43 GBq/μmol. (Poschenrieder et al. 2016a) ), the 64 Cu-labeled NOTA-peptide is slightly more lipophilic, whereas its lipophilicity is increased by more than an order of magnitude compared to [ 68 Ga]pentixafor (log P = -2.90 (Gourni et al. 2011) Cell uptake and efflux studies Figure 2a shows the CXCR4-specific total cellular uptake and internalization of [ 64 Cu]NOTA-pentixather into Chem-1 cells, stably transfected with hCXCR4. The preferential use of this adherent cell line for the internalization and externalization studies was based on our previous observation that the determination of cellular uptake kinetics in suspension cells (such as Jurkat or Daudi cells ) is oftentimes biased by the experimental conditions (repeated centrifugation and resuspension steps), challenging cell viability and thus leading to inconsistent and irreproducible results. This effect was not encountered using Chem-1 cells. As shown in Fig. 2a , the total Cu]NOTA-pentixather activity increases steadily over time, reaching approximately 12 and 22% of the added activity after 15 and 120 min, respectively. Internalization reaches a maximum after 30 min (~10%) and decreases to~5% after 120 min. An exemplary efflux study is shown in Fig. 2b and reveals that 28% of the initial cellular [ 64 Cu]NOTA-pentixather activity are retained after 120 min of externalization.
Biodistribution studies
Biodistribution data of [
64 Cu]NOTA-pentixather at 1.5 h p.i. (n = 5, black bars) and 24 h p.i. (n = 6, grey bars) in Daudi-lymphoma-bearing SCID mice are summarized in Fig. 3 . Given the fact that Jurkat cells, which are generally used for the determination of CXCR4 affinity, are not tumorigenic in mice and to ensure comparability of data with previous studies (Poschenrieder et al. 2016a; Wester et al. 2015; Schottelius et al. 2015) , the Daudi lymphoma model was also used in this study. Blood clearance of [ 64 Cu]NOTA-pentixather was fast (1.1 ± 0.2% ID/g at 1.5 h p.i.), and activity 2011)), a certain extent of hepatobiliary excretion and thus non-specific accumulation in the liver and intestines were observed (7.2 ± 1.1 and 5.0 ± 2.8% ID/g, respectively), while activity accumulation in the kidney was comparably low (3.8 ± 0.5% ID/g). Tumor uptake of [ 64 Cu]NOTA-pentixather was significantly higher than tracer accumulation in all other organs (13.1 ± 1.5% ID/g), underlining its excellent CXCR4 targeting efficiency. Coinjection of 2 mg/kg AMD3100 (Fig. 3 , white bars) resulted in a reduction of tumor uptake by 88% (1.5 h p.i.), demonstrating the high CXCR4-specificity of [ 64 Cu]NOTA-pentixather accumulation in the lymphoma xenograft. The resulting tumor-to-organ ratios at 1.5 and 24 h p.i. are summarized in Fig. 4 . While the tumorto-background ratios for most tissues remain unchanged or decrease within the observation period, t/blood and t/intestine ratios increase 1.3 and 2.4 fold between 1.5 and 24 h p.i., respectively.
Small animal PET imaging
Representative PET/CT images of [ 64 Cu]NOTA-pentixather in Daudi-lymphoma bearing SCID mice at 1 h, 3.5 h, and 24 h p.i. are shown in Fig. 5 . Besides high and CXCR4-specific uptake of [ 64 Cu]NOTA-pentixather in the Daudi lymphoma xenograft, some background activity uptake is observed in the liver, the gall bladder, and the intestines. Upon coinjection with 50 μg AMD3100, tumor accumulation is reduced to background levels (Fig. 5b) , demonstrating that tumor uptake of [ 64 Cu]NOTA-pentixather is almost exclusively CXCR4-mediated. 
Metabolite analysis and EDTA challenge
To investigate the in vitro stability of [ 64 Cu]NOTA-pentixather, the tracer was incubated both in human serum at 37°C and in 0.1 M EDTA at pH = 2.5 and physiological pH (7.4) at RT for different time points up to 24 h (Fig. 7) . The in vivo stability of the tracer was investigated via metabolite studies in mice. Radio-HPLC analysis of urine and blood as well as tissue homogenates from liver and kidney showed that 98% intact [
64 Cu]NOTA-pentixather were present in blood and urine, while 68 and 24% intact tracer were found in liver and kidney, respectively. Despite reasonable thermodynamic stability, macrocyclic Cu 2+ complexes, e.g. oxide dismutase (SOD)) or proteins (e.g. caeruloplasmin and metallothionein) are highly abundant in liver or kidney and are most probably responsible for inferior kinetic inertness of the tracer in these organs (Bass et al. 2000; McArdle et al. 1999; Terao & Owen 1973; Blower et al. 1996; Valentine et al. 1999; Musci et al. 1999 De Silva et al. 2011; Nimmagadda et al. 2010; Jacobson et al. 2009 ). The latter providing very high and specific tumor uptake; however both tracers also show high uptake in the liver and kidneys. In contrast to 64 Cu-NOTA-pentixather and 64 Cu-T140 derivatives, uptake in the liver was mostly specific; therefore, the authors suggest a CXCR4-independent component (Jacobson et al. 2009 ). Moreover, as tested by [ 64 Cu]CuCl 2 injected mice, transchelation did not contribute to the increased uptake in kidneys or liver. However, after 10 h, % ID/g values in the blood increased which hints towards transchelation at delayed time points (De Silva et al. 2011 ).
DOTA-complexes, are oftentimes prone to in vivo dissociation
In the case of [ 64 Cu]NOTA-pentixather, the overall high stability is also reflected by increasing tumor-to-blood ratios, which, accompanied with its promising CXCR4-targeting properties, resulted in high-contrast PET/CT images of lymphoma xenografts (Fig. 5) . As shown in TACs, tumor uptake was higher than activity accumulation in all other tissues already at 17 min p.i., highlighting the efficient CXCR4-targeting and fast clearance of the tracer from non-target tissue with comparably low unspecific background accumulation at all time points (Fig. 6) . However, at 1.5 and 3.5 h p.i, some background accumulation in the excretion organs was still visible. As discussed, this hepatic and intestinal activity uptake is most probably the result of a slightly delayed overall clearance due to the enhanced lipophilicity of the tracer compared to [ 68 Ga]pentixafor. At 24 h p.i., tracer clearance from the body is almost complete, resulting in very low residual activity in liver and tumor. Modest internalization and fast externalization kinetics (Fig. 2) contribute to the fast clearance from tumor tissue. Although, its use for endoradiotherapeutic purposes is therefore limited, [ 64 Cu]NOTApentixather proved as valuable PET agent for imaging of CXCR4 expression in vivo.
Conclusion
In summary we were able to successfully transfer our 'pentixafor/pentixather'-based CXCR4-targeting technology to a promising analog for 64 Cu-labeling. Due to the suitable in vitro and in vivo stability of the tracer, its rapid and specific activity accumulation in the Daudi xenograft, as well as rapid clearance from the background, PET images resulted in a clear delineation of the experimental tumors in vivo. However, fast clearance from the human xenografts and some uptake in the excretory organs, attributed to its slightly enhanced lipophilicity, limit the tracer's efficiency for a further therapeutic transfer with 67 Cu. The initial results recommend further investigations with [ 64 Cu]NOTA-pentixather for CXCR4-PET imaging.
Methods
General procedures and syntheses of the peptides were performed as described (Poschenrieder et al. 2016b) .
[ ) were added to an aqueous solution containing 150 μL 0.4 M NaOAc buffer (pH = 5.5) and 5 nmol of NOTA-pentixather. After heating to 60°C for 10 min, the reaction mixture was allowed to cool to RT, and [ 64 Cu]NOTA-pentixather was isolated via solid phase extraction using a C8-light cartridge (Waters). The product was eluted from the solid phase using a small volume of ethanol containing 0.5% (v/v) acetic acid.
EDTA-challenge
For challenging experiments, 4 MBq of [ 64 Cu]NOTA-pentixather were incubated in 0.1 M EDTA at different pH values (2.5 and 7.4) for a minimum of 24 h. At specific time points, samples were analyzed via radio-TLC using silica gel impregnated chromatography paper (Agilent Technologies, CA, USA) and 0.1 M phosphate buffer (pH = 7.4) containing 10 mM sodium EDTA as the mobile phase.
Determination of lipophilicity and serum stability
The lipophilicity and serum stability of [ 64 Cu]NOTA-pentixather were determined as described previously (Poschenrieder et al. 2016a) . Briefly, to a solution of app. 2 kBq of radiolabelled peptide in 500 μL of PBS (pH 7.4), 500 μL of octanol were added (n = 6). Vials were vortexed vigorously for 3 min. To achieve quantitative phase separation, the vials were centrifuged at 14,600 · g for 6 min in a Biofuge 15 (Heraeus Sepatech, Osterode, Germany). The activity concentrations in 100 μL samples of both the aqueous and the organic phase were measured in a gamma counter, and the log P ow was calculated.
In vitro studies 120 min at RT. After centrifugation and repeated washing steps, the amount of free and bound radioligand were quantified for each sample using a γ-counter, and IC 50 values were calculated using GraphPad Prism 6.01 software. Internalization and efflux studies were performed as described (Poschenrieder et al. 2016a ) using Chem-1 cells stably transfected with hCXCR4 (HTS004C, Merck Millipore, Darmstadt, Germany). Briefly, adherent cells in 24-well plates (150,000/well) were incubated with 1 nM [ 64 Cu]NOTA-pentixather in the absence (total binding) or presence of 100 μM AMD3100 (non-specific binding) at 37°C for different time intervals up to 60 min. Subsequently, the amount of free, membrane-bound, and internalized activity were quantified for each sample using a γ-counter. For efflux studies, [ 64 Cu]NOTA-pentixather was first allowed to internalize at 37°C for 45 min. Then, the supernatant was exchanged by ligand-free assay medium, and efflux of [ 64 Cu]NOTA-pentixather over time was investigated (37°C). The remaining total cellular activity (membrane-bound + internalized activity) at different time points was quantified as described above.
In vivo studies
All animal studies were approved by the local authorities (No.: 55.2-1-54-2532-71-13) and are in compliance with the institution's guidelines. For metabolite analysis, 18 MBq of [
64 Cu]NOTA-pentixather in a total volume of 200 μL of phosphate-buffered saline (PBS) were injected into the tail vein of a CB17 SCID mouse. At 1 h p.i., the animal was sacrificed and blood, urine, kidneys, and liver were collected. After sample preparation (Weineisen et al. 2014) Cu]NOTA-pentixather under 'tracer only' (n = 2) as well as blocking conditions (coinjection of 2 mg/kg AMD3100, n = 1) was performed at three different time points (dynamic PET imaging for 1 h, followed by static image acquisition for 15 min after 3.5 and 24 h) using an Inveon Siemens μPET scanner. PET/CT images were reconstructed by a two-dimensional ordered subset expectation maximum (2D-OSEM) algorithm with no attenuation correction. Image analysis was performed using the Inveon software, and results were calculated as %ID/g. For biodistribution studies, the mice were sacrificed at 1.5 h (n = 5) and 24 h (n = 6) p.i., tissues and organs of interest were dissected, weighed, and counted for radioactivity in a γ-counter. The percentage of injected dose per gram of tissue (% ID/g) was calculated; data are presented as mean ± SD. 
